Tildrakizumab for the treatment of hidradenitis suppurativa in patients previously treated with adalimumab: a 30-month experience
Clinical and Experimental Dermatology · 2023
DOI: 10.1093/ced/llad215 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Dermatology, 2023. Verfasst von Ben Koszegi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, St George Hospital, Sydney, NSW,Australia. Hauptthemen laut MEDLINE: Hidradenitis Suppurativa. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 5 Literaturangaben. Gefördert von: Sun Pharmaceuticals.
Abstract (Originalsprache)
Our case series findings indicate that tildrakizumab treatment in patients with hidradenitis suppurativa who previously received adalimumab demonstrated an initial improvement in disease activity within the first 6 months. However, this overall trend was not sustained beyond the 6-month mark. Nevertheless, it is noteworthy that patients who underwent long-term follow-up on tildrakizumab experienced ongoing disease activity but showed a reduction in Dermatology Life Quality Index scores.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, St George Hospital, Sydney, NSW,Australia.
- Faculty of Medicine, University of New South Wales, Sydney, NSW,Australia.
ORCID-Profile: Ben Koszegi, Anna Wilson, Corey Stone, Fanny Satgé, Timothy L Cowan, Dédée F Murrell
Förderung
- Sun Pharmaceuticals
Zitieren
APA
Koszegi, B., Wilson, A., Stone, C., Satgé, F., Cowan, T. L., & Murrell, D. F. (2023). Tildrakizumab for the treatment of hidradenitis suppurativa in patients previously treated with adalimumab: a 30-month experience. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llad215
Vancouver
Koszegi B, Wilson A, Stone C, Satgé F, Cowan TL, Murrell DF. Tildrakizumab for the treatment of hidradenitis suppurativa in patients previously treated with adalimumab: a 30-month experience. Clinical and Experimental Dermatology. 2023. doi:10.1093/ced/llad215
BibTeX
@article{Koszegi2023,
author = {Koszegi, Ben and Wilson, Anna and Stone, Corey and Satgé, Fanny and Cowan, Timothy L and Murrell, Dédée F},
title = {Tildrakizumab for the treatment of hidradenitis suppurativa in patients previously treated with adalimumab: a 30-month experience},
journal = {Clinical and Experimental Dermatology},
year = {2023},
doi = {10.1093/ced/llad215}
}
EUVIMED